Eppendorf North America Bio-Expo Live June 2026: Upstream Bioprocessing

Scaling cell and gene therapy processes from R&D to commercial manufacturing introduces new risks, especially when sensitive cell lines require stable gas control, low-shear agitation, and precise feeding. Those challenges often intensify in GMP settings, where equipment changes, software differences, and manual setup variability can disrupt process consistency. A scalable control strategy helps reduce those gaps by carrying the same approach from development through production. Automated sensor calibration guidance, mathematical scaling tools, audit trails, and validation-ready documentation can support smoother tech transfer, stronger reproducibility, and simpler compliance.

Discover practical ways to improve scale-up and clinical manufacturing readiness.